Type II Variation for Breyanzi Listed in February’s CHMP Agenda
Here is a brief preview of this blast: On Monday, February 20, the CHMP agenda for February was released. For the second time, Breyanzi (BMS’s CD19 CAR-T) was listed under the ‘Type II Variations – Opinion or Requests for Supplementary Information’ section in 2L DLBCL Transplant Intended (TI) patients.
About The Author
The Celltelligence Team
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.